– Zalutumumab, a fully human IgG1 monoclonal antibody, exhibits high affinity for the epidermal growth factor receptor (EGFR), selectively targeting its domain III. It functions by inhibiting the binding of the epidermal growth factor (EGF) and obstructing the receptor’s active conformation through steric hindrance. With EC50 values of 7 nM for its IgG and 19 nM for the Fab fragment, Zalutumumab demonstrates potent interaction capabilities. This compound is primarily utilized in cancer research [1] [2] [3].